Blog > Hot Stock Pick of the Week > Blog article: Biotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)
 | Email This Article Email This Article  | 

Biotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)

Posted May 22, 2008

A Today’s Financial News Research Report:

‘This Maryland-based biotechnology firm develops treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.’ – Laura Cadden

By Laura Cadden, TodaysFinancialNews.com
Today’s Financial News feed provides an independent and practical perspective on the U.S. and global investment markets.

RSS feed Subscribe in a Reader or Subscribe via e-mail

Baltimore (TFN): The following is the TFN Hot Stock Pick for this week selected by Laura Cadden. Watch the video.

The company I’ve selected for this week is a Maryland-based biotechnology firm working on treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.

Osiris Therapeutics, Inc. creates therapeutic drugs from human mesenchymal stem cells (MSCs) retrieved from bone marrow donated by healthy adult volunteers.

Bone regeneration = big bucks

Earlier this month, Osiris announced the sale of its Osteocel unit to NuVasive for $85 million.

Osteocel promotes bone regeneration and is used in spinal fusion and other orthopedic procedures.

This deal provides Osiris with the money and ability to focus on the next generation of revolutionary products… products like Chondrogen, which works on the regeneration of knee cartilage, and the multi-purpose Prochymal.

The incredible potential of Prochymal

Learn how to trade and profit using currencies.

With iFOREX, you’ll get one-on-one training and 24-hour support.

The most exciting biologic drug in Osiris’ repertoire is Prochymal. Designed to reverse cellular damage, its applications seem limitless.

The most vaunted use is as a treatment for Graft-versus-host disease. Early testing was credited with saving the lives of seven of twelve children in the advanced critical stages of the disease. As a result, the drug is currently in a Phase III trial and has been granted Fast Track status by the FDA.

If all goes as well as anticipated,Prochrymal would be the first approved stem cell therapy in the world.

But it does’t end there…

The positive effects of Prochymal on the gastrointenstinal symptoms of graft-versus-host disease revealed additional prospects.

Osiris has begun a Phase III program using the drug in the treatment of Crohn’s Disease.

Prochymal has also shown results in the repair of heart tissue following a heart attack. In March, Phase I trial results showed patients receiving the drug had markedly less cardiac arrythmias as well as significant improvements in heart and lung function.

Laura Cadden on TFN Hot Stock Pick of the WeekRather watch the video? Click here.

The Department of Defense has bought into this technology

In January, Osiris, partnered with Genzyme, was awarded a $224.7 million contract by the Department of Defense to develop and stockpile Prochymal for the treatment of gastrointestinal injury resulting from acute radiation syndrome.

This opens the company up to a whole new client sector.

Like many research-focused biotechs, Osiris operates at a net loss. For the first quarter of 2008, the loss amounted to $15.6 million – that’s up from $11.5 million the year prior.

The main reason for this increase is the additional research and testing involving Prochymal.

The first-quarter report listed an available cash flow of $42 million and a credit line of $30 million through its primary backer, Friedli Corporate Finance.

A sound investment

Osiris Therapeutics, Inc.
7015 Albert Einstein Drive
Columbia, MD 21046
Phone: 443-545-1800
Fax: 443-545-1701
Web Site: http://www.osiristx.com

Some estimate that the market for stem cell therapy to be around $20 billion by 2010.

Besides the opportunities presented by Prochymal, Osiris has 47 patents for their cutting-edge technology in the U.S. and over 200 foreign patents owned or licensed.

I recommend you buy Osiris Therapeutics, Inc. (OSIR:NASDAQ) at or under $15.50. My conservative10-month target for the stock price is $18.
This report is brought to you by Today’s Financial News – the Premier FREE Investment News Service!
RSS feed Subscribe in a Reader or Subscribe via e-mail

Related Articles


Posted by Laura Cadden · Filed Under Hot Stock Pick of the Week 

Comments

close Reblog this comment
Powered by Disqus · Learn more
blog comments powered by Disqus